Alzheimer is the sixth leading cause of death in the United States and, if extrapolated globally, the market for preventions, treatments and cures for this crippling disease is enormous, notes Alzamend Neuro.
Since 1990, life expectancy has increased by six years and the global average continues to rise.
Alzamend Neuro is an early-stage clinical stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease, bipolar disorder, major depressive disorder (MDD) and post-traumatic stress disorder (PTSD).
With the increase in the average age of the population in developed countries, the prevalence of deteriorating neurological diseases has also increased.
According to the Alzheimer’s Association, in the United States alone, one in nine people over the age of 65 has Alzheimer’s, and some 6.2 million Americans are currently living with it.
This number is projected to increase to 13 million by 2050 if medical advances are not developed to prevent, slow or cure the disease.
Many Alzheimer’s associations believe that the actual number of adults with Alzheimer’s may be much higher, as current statistics do not take into account deaths from complications or related diseases such as pneumonia or heart attack. Death certificates only record the most immediate cause.
The fastest growing age group in the United States is the «85+» age group, within which one in three individuals has Alzheimer’s disease.
Alzheimer
With two product candidates, Alzamend Neuro aims to bring treatments or cures to market as soon as possible.
Too many individuals, patients and caregivers suffer from the burden created by these devastating, and often fatal, diseases.
Alzamend Neuro’s primary target, Alzheimer’s, is among the most feared diseases (second only to cancer) among Americans, according to a 2011 survey conducted by the Harvard School of Public Health.
Outlook
Existing treatments for Alzheimer’s only temporarily alleviate symptoms, but do not slow or halt the progression of the disease, which currently affects about 6.2 million Americans and that number is projected to increase to 13 million individuals by 2050.
Alzheimer’s also affects more than 11 million Americans who provide about 16 billion hours of unpaid care annually, valued at $272 billion, according to Alzheimer’s Association data.
In 2022, estimated healthcare costs for treating people with Alzheimer’s in the United States will be $321 billion, including $206 billion in Medicare and Medicaid payments.
These costs could rise to $1 trillion a year by 2050 if a permanent treatment or cure for Alzheimer’s is not found, the Alzheimer’s Association reported.
